Cargando…

Efficient oral vaccination by bioengineering virus-like particles with protozoan surface proteins

Intestinal and free-living protozoa, such as Giardia lamblia, express a dense coat of variant-specific surface proteins (VSPs) on trophozoites that protects the parasite inside the host’s intestine. Here we show that VSPs not only are resistant to proteolytic digestion and extreme pH and temperature...

Descripción completa

Detalles Bibliográficos
Autores principales: Serradell, Marianela C., Rupil, Lucía L., Martino, Román A., Prucca, César G., Carranza, Pedro G., Saura, Alicia, Fernández, Elmer A., Gargantini, Pablo R., Tenaglia, Albano H., Petiti, Juan P., Tonelli, Renata R., Reinoso-Vizcaino, Nicolás, Echenique, José, Berod, Luciana, Piaggio, Eliane, Bellier, Bertrand, Sparwasser, Tim, Klatzmann, David, Luján, Hugo D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6341118/
https://www.ncbi.nlm.nih.gov/pubmed/30664644
http://dx.doi.org/10.1038/s41467-018-08265-9
Descripción
Sumario:Intestinal and free-living protozoa, such as Giardia lamblia, express a dense coat of variant-specific surface proteins (VSPs) on trophozoites that protects the parasite inside the host’s intestine. Here we show that VSPs not only are resistant to proteolytic digestion and extreme pH and temperatures but also stimulate host innate immune responses in a TLR-4 dependent manner. We show that these properties can be exploited to both protect and adjuvant vaccine antigens for oral administration. Chimeric Virus-like Particles (VLPs) decorated with VSPs and expressing model surface antigens, such as influenza virus hemagglutinin (HA) and neuraminidase (NA), are protected from degradation and activate antigen presenting cells in vitro. Orally administered VSP-pseudotyped VLPs, but not plain VLPs, generate robust immune responses that protect mice from influenza infection and HA-expressing tumors. This versatile vaccine platform has the attributes to meet the ultimate challenge of generating safe, stable and efficient oral vaccines.